We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
GRAL

Price
45.63
Stock movement down
-2.81 (-5.80%)
Company name
GRAIL, LLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Market cap
1.64B
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-08-27

DIVIDENDS

GRAL does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open49.58
Daily high49.58
Daily low44.44
Daily Volume2.22M
All-time high55.02
1y analyst estimate40.50
Beta-
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date11 Nov 2025

Downside potential

Loading...
Downside potential data
GRALS&P500
Current price drop from All-time high-17.07%-3.04%
Highest price drop-61.12%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-25.48%-11.04%
Avg time to new high16 days12 days
Max time to new high98 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
GRAL (GRAIL, LLC) company logo
Marketcap
1.64B
Marketcap category
Small-cap
Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Employees
1000
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...